seladelpar Livdelzi PBC
Selected indexed studies
- New Treatment Paradigms in Primary Biliary Cholangitis. (Clin Gastroenterol Hepatol, 2023) [PMID:36809835]
- Primary biliary cholangitis: Personalizing second-line therapies. (Hepatology, 2025) [PMID:39707635]
- Seladelpar: First Approval. (Drugs, 2024) [PMID:39572508]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Seladelpar. (2012) pubmed
- Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. (2024) pubmed
- Seladelpar: First Approval. (2024) pubmed
- Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. (2023) pubmed
- New Treatment Paradigms in Primary Biliary Cholangitis. (2023) pubmed
- Primary biliary cholangitis: Personalizing second-line therapies. (2025) pubmed
- Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis. (2025) pubmed
- PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales. (2023) pubmed
- Current Landscape and Evolving Therapies for Primary Biliary Cholangitis. (2024) pubmed
- The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine. (2025) pubmed